LIGAND PHARMACEUTICALS INCORPORATED — Revenue by Fiscal Year

17 fiscal years, as filed with the SEC; every row links its evidence fact.

Cite as: FACTANKER, https://factanker.com/entity/4a040647-8ad5-4cd9-aec2-d3797e63cec5/serie/revenue

Fiscal yearRevenuePeriodEvidence
FY 2025$268.1M2025-01-01 – 2025-12-31evidence 0000886163-26-000006
FY 2024$167.1M2024-01-01 – 2024-12-31evidence 0000886163-25-000012
FY 2023$131.3M2023-01-01 – 2023-12-31evidence 0000886163-24-000009
FY 2022$196.2M2022-01-01 – 2022-12-31evidence 0000886163-23-000007
FY 2021$241.5M2021-01-01 – 2021-12-31evidence 0000886163-23-000007
FY 2020$163.6M2020-01-01 – 2020-12-31evidence 0000886163-23-000007
FY 2019$120.3M2019-01-01 – 2019-12-31evidence 0000886163-20-000025
FY 2018$251.5M2018-01-01 – 2018-12-31evidence 0000886163-19-000041
FY 2017$141.1M2017-01-01 – 2017-12-31evidence 0000886163-18-000030
FY 2016$109.0M2016-01-01 – 2016-12-31evidence 0000886163-19-000041
FY 2015$27.7M2015-01-01 – 2015-12-31evidence 0000886163-16-000149
FY 2014$28.5M2014-01-01 – 2014-12-31evidence 0000886163-15-000028
FY 2013$9.4M2013-01-01 – 2013-12-31evidence 0000886163-14-000119
FY 2012$12.1M2012-01-01 – 2012-12-31evidence 0000886163-14-000119
FY 2011$12.1M2011-01-01 – 2011-12-31evidence 0001193125-12-075655
FY 2010$23.5M2010-01-01 – 2010-12-31evidence 0001193125-12-075655
FY 2009$38.9M2009-01-01 – 2009-12-31evidence 0001193125-12-075655
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).

LIGAND PHARMACEUTICALS INCORPORATED — all facts · Net Income · Operating Income